Cellid Co. Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: -0.031x

Cellid Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Cellid Co. Ltd (299660) has a cash flow conversion efficiency ratio of -0.031x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.30 Billion ≈ $-1.56 Million USD) by net assets (₩74.21 Billion ≈ $50.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cellid Co. Ltd (2016–2025)

Cash flow conversion efficiency of Cellid Co. Ltd from 2016 to 2025. This chart illustrates how Cellid Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 299660 share price today for real-time trading data and today's change.

Cellid Co. Ltd Cash Flow Conversion Ratio Explained

Cellid Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cellid Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cellid Co. Ltd ranked by their cash flow conversion efficiency. Also see 299660 stock market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Structural Monitoring Systems Plc AU:SMN	0.187x
Appasia Bhd KLSE:0119	-0.022x
Eternal Energy Public Company Limited BK:EE	-0.078x
Ariana Resources Plc AU:AA2	-0.024x
Relief Therapeutics Holding AG SW:RLF	-0.115x
China Television Co TW:9928	-0.016x
Nextcom TA:NXTM	0.183x
GFG Resources Inc V:GFG	-0.013x

Annual Cash Flow Conversion Efficiency for Cellid Co. Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Cellid Co. Ltd from 2016 to 2025. Review 299660 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩74.21 Billion ≈ $50.29 Million	₩-10.22 Billion ≈ $-6.92 Million	-0.138x	+31.65%
2024-12-31	₩51.20 Billion ≈ $34.70 Million	₩-10.32 Billion ≈ $-6.99 Million	-0.201x	-14.66%
2023-12-31	₩40.50 Billion ≈ $27.44 Million	₩-7.12 Billion ≈ $-4.82 Million	-0.176x	+67.73%
2022-12-31	₩22.44 Billion ≈ $15.21 Million	₩-12.22 Billion ≈ $-8.28 Million	-0.544x	-157.14%
2021-12-31	₩38.76 Billion ≈ $26.27 Million	₩-8.21 Billion ≈ $-5.56 Million	-0.212x	-166.09%
2020-12-31	₩47.30 Billion ≈ $32.05 Million	₩-3.76 Billion ≈ $-2.55 Million	-0.080x	-112.62%
2019-12-31	₩51.33 Billion ≈ $34.79 Million	₩-1.92 Billion ≈ $-1.30 Million	-0.037x	+74.67%
2018-12-31	₩13.50 Billion ≈ $9.15 Million	₩-1.99 Billion ≈ $-1.35 Million	-0.148x	-159.53%
2017-12-31	₩-5.53 Billion ≈ $-3.75 Million	₩-1.37 Billion ≈ $-929.53K	0.248x	-96.60%
2016-12-31	₩-205.83 Million ≈ $-139.49K	₩-1.50 Billion ≈ $-1.02 Million	7.306x	--

About Cellid Co. Ltd

KQ:299660 Korea Biotechnology

Market Cap

$36.33 Million

₩53.61 Billion KRW

Market Cap Rank

#22872 Global

#1518 in Korea

Share Price

₩1817.00

Change (1 day)

+3.83%

52-Week Range

₩1025.00 - ₩4110.00

All Time High

₩127128.20